Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 28;7(4):644-648.
doi: 10.1182/bloodadvances.2022007625.

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Suzette Girgis  1 , Shun Xin Wang Lin  1 , Kodandaram Pillarisetti  1 , Raluca Verona  1 , Diego Vieyra  1 , Tineke Casneuf  2 , Damien Fink  1 , Xin Miao  1 , Yang Chen  1 , Tara Stephenson  1 , Arnob Banerjee  1 , Brandi W Hilder  1 , Jeffery Russell  1 , Jeffrey Infante  1 , Yusri Elsayed  1 , Jennifer Smit  1 , Jenna D Goldberg  1
Affiliations

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Suzette Girgis et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: D.F., Y.C., and J.R. are former employees of Janssen Research & Development and may own stock/stock options in Johnson & Johnson. The remaining authors are currently employees of Janssen Research & Development and may own stock/stock options in Johnson & Johnson.

Figures

Figure 1.
Figure 1.
Change in sBCMA levels on cycle 3, day 1 vs baseline according to depth of response to bispecific treatment. (A) sBCMA levels relative to depth of response for teclistamab. Patients received weekly intravenous (0.0003-0.72 mg/kg) or subcutaneous (80-3.0 mg/kg) doses of teclistamab. Cycle 3, day 8 data were used for 3 patients who had missing cycle 3, day 1 data. (B) sBCMA levels relative to depth of response for talquetamab. Cycle 3, day 8 data were used for 2 patients who had missing cycle 3, day 1 data. Data are not shown for 3 patients with sBCMA change >500% (508% [SD], 1201% [SD], and 2620% [SD]). Median percentage sBCMA change (minimum; maximum) shown. IV, intravenous; MR, minimal response; N/A, not applicable; PD, progressive disease; SC, subcutaneous; SD, stable disease.
Figure 2.
Figure 2.
Baseline sBCMA and response to treatment. (A) Teclistamab. (B) Talquetamab. Data cutoff dates for response were 24 December 2020 (MajesTEC-1) and 2 January 2021 (MonumenTAL-1); median (range) shown. Patients were categorized as responders or nonresponders based on their best responses. IV, intravenous; SC, subcutaneous.
See this image and copyright information in PMC

References

    1. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985–1005. - PMC - PubMed
    1. Dettman EJ. Expression of myeloma cell and soluble B-cell maturation antigen (BCMA) in relapsed and refractory multiple myeloma patients treated with GSK2857916 in BMA117159. Blood. 2018;132(suppl 1):1977.
    1. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290–296. - PMC - PubMed
    1. Frigyesi I, Adolfsson J, Ali M, et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood. 2014;123(9):1336–1340. - PubMed
    1. Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012;42(9):953–960. - PubMed

Publication types

Substances